ACADIA Pharmaceuticals Inc. (ACAD)
Automate Your Wheel Strategy on ACAD
With Tiblio's Option Bot, you can configure your own wheel strategy including ACAD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ACAD
- Rev/Share 5.9726
- Book/Share 4.5875
- PB 4.8588
- Debt/Equity 0.0732
- CurrentRatio 2.8789
- ROIC 0.2413
- MktCap 3730498980.0
- FreeCF/Share 0.2974
- PFCF 75.2086
- PE 16.2448
- Debt/Assets 0.0495
- DivYield 0
- ROE 0.3532
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | ACAD | Deutsche Bank | Hold | Buy | -- | $35 | May 21, 2025 |
| Initiation | ACAD | Deutsche Bank | -- | Hold | -- | $22 | Feb. 11, 2025 |
| Downgrade | ACAD | Guggenheim | Buy | Neutral | $23 | $20 | Jan. 3, 2025 |
| Resumed | ACAD | Raymond James | -- | Market Perform | -- | -- | Oct. 10, 2024 |
News
GSK or ACAD: Which Is the Better Value Stock Right Now?
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of GSK (GSK) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?
Read More
ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.
Read More
Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation
Published: May 16, 2025 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware ruled in favor of Acadia regarding its ‘721 formulation patent for NUPLAZID® (pimavanserin), Acadia's drug for the treatment of Parkinson's Disease Psychosis. In today's order, the Court ruled in favor of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA (Abbreviated.
Read More
ACADIA Pharmaceuticals: Advancing On Several Fronts
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Positive
ACADIA Pharmaceuticals posted better-than-expected Q1 results earlier this month. The company has a rock solid balance sheet and advancing a couple of key drug candidates within its pipeline. An updated analysis around ACADIA Pharmaceuticals follows in the paragraphs below.
Read More
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
Read More
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Al Kildani - SVP of IR & Corporate Communications Catherine Owen Adams - CEO Tom Garner - COO Elizabeth Thompson - EVP and Head of R&D Mark Schneyer - EVP and CFO Conference Call Participants Ritu Baral - TD Cowen Tessa Romero - JPMorgan Ash Verma - UBS Elaine Kim - Canter Basma Radwan - Leerink Partners David Huang - Deutsche Bank Tazeen Ahmad - Bank of America Yatin Suneja - Guggenheim Joel Beatty - Baird Sumant Kulkarni - Canaccord Genuity Malcolm …
Read More
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago.
Read More
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
Read More
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Negative
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Negative
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Read More
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Negative
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
Read More
ACADIA Pharmaceuticals Inc. (ACAD) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q4 2024 Results Conference Call February 26, 2025 4:30 PM ET Company Participants Al Kildani - SVP of Investor Relations & Corporate Communications Catherine Owen Adams - CEO Tom Garner - COO Elizabeth Thompson - EVP, Head of R&D Mark Schneyer - EVP, CFO Conference Call Participants Ami Fadia - Needham & Company Tessa Romero - JPMorgan Joel Beatty - Baird Tazeen Ahmad - Bank of America Securities Gregory Renza - RBC Capital Markets Charles Duncan - Cantor Sumant Kulkarni - Canaccord Genuity LLC Operator Good day, ladies and gentlemen, and welcome to the ACADIA …
Read More
About ACADIA Pharmaceuticals Inc. (ACAD)
- IPO Date 2004-05-27
- Website https://www.acadia-pharm.com
- Industry Biotechnology
- CEO Ms. Catherine E. Owen Adams
- Employees 653